Medigen Biotechnology Corp.
3176
Rank in Stocks
#18278
Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated... Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural killer cells, and MAGICELL-GDT, a T-cell-based treatment. A significant pipeline asset for Medigen is OBP-301. This therapeutic has completed Phase I clinical trials for combination therapy in esophageal cancer in Japan. It is currently being evaluated in ongoing Phase I trials in Japan, combining it with immune checkpoint inhibitors (ICIs) for esophageal cancer, and has advanced to Phase II studies in the United States, investigating its use with ICIs for both esophageal and gastric cancer. Established in 1999, Medigen Biotechnology Corp. maintains its corporate headquarters in Taipei, Taiwan.
Share Price
$0.99379335
Last synced: 2026-11-10
Market Cap
$138.44M
Change (1 day)
0.46%
Change (1 year)
3.53%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Medigen Biotechnology Corp. (3176)
Category
Healthcare
Operating Margin for Medigen Biotechnology Corp. (3176)
Operating Margin as of November 2026 TTM: -18.42%
According to Medigen Biotechnology Corp.'s latest financial reports, its current operating margin (TTM) is -18.42%. At the end of 2025 the company had an operating margin of -9.92%.
Operating Margin history for Medigen Biotechnology Corp. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -18.42% | 85.69% |
| 2025 | -9.92% | -35.37% |
| 2024 | -15.35% | -85.59% |
| 2023 | -106.51% | -32.53% |
| 2022 | -157.87% | -884.64% |
| 2021 | 20.12% | -113.55% |
| 2020 | -148.52% | 7.61% |
| 2019 | -138.02% | -26.27% |
| 2018 | -187.19% | 23.77% |
| 2017 | -151.24% | -19.39% |
| 2016 | -187.63% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -102.10% |
US
|
|
| -149.01% | -91.91% |
US
|
|
| 25.57% | -101.39% |
AU
|
|
| 31.23% | -101.70% |
BE
|
|
| 29.35% | -101.59% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Medigen Biotechnology Corp.'s operating margin
What is Medigen Biotechnology Corp.'s operating margin?
Medigen Biotechnology Corp.'s operating margin is -18.42%, as of Nov 2026.
What was Medigen Biotechnology Corp.'s operating margin in 2025?
In 2025, Medigen Biotechnology Corp.'s operating margin was -9.92%, compared with -15.35% in 2024.
How has Medigen Biotechnology Corp.'s operating margin changed since 2020?
From 2020 to 2025, Medigen Biotechnology Corp.'s operating margin was highest in 2021 (20.12%) and lowest in 2022 (-157.87%).
How does Medigen Biotechnology Corp.'s operating margin compare with similar companies?
Medigen Biotechnology Corp.'s operating margin (-18.42%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.